• University of Tennessee (B.A., 1983, magna cum laude
  • Georgetown University Law Center (J.D., 1986, cum laude)


  • District of Columbia
  • United States Supreme Court
  • United States Courts of Appeals for the Second, Third, Fourth, Fifth, Sixth, Eighth, Ninth, Tenth, and Eleventh Circuits
  • United States District Courts for the District of Colorado, the District of Columbia, the Northern District of Florida, and the District of Maryland

Katharine R. Latimer's complex litigation practice emphasizes trials and appeals in the defense of pharmaceutical and medical device product liability and toxic tort claims.  The National Law Journal has profiled three of her most significant victories as top defense wins of the year (Crowson v. Davol, Inc. in 2005, Glastetter v. Novartis Pharm. Corp. in 2001, and Warren v. Sandoz Pharm. Corp. in 1998).  In 2013, Ms. Latimer secured a 7-1 defense verdict for her client Novartis Pharmaceuticals Corporation in the second bellwether case chosen for trial in serial litigation consolidated in New Jersey over Novartis’s drugs Aredia® and Zometa®.  Meng v. Novartis Pharm. Corp., No. MID-L-7670-07-MT (N.J. Super. Ct. Law Div. May 15, 2013).  The litigation involves the claim that the drugs cause a “signature disease” known as osteonecrosis of the jaw (“ONJ”).  After deliberating for fewer than six hours, the Meng jury rejected the plaintiff’s failure-to-warn claim.  Ms. Latimer also won the first bellwether trial in the same New Jersey litigation in 2010.  Bessemer v. Novartis Pharm. Corp., MID-L-1835-08-MT (N.J. Super. Ct. Law Div. Oct. 22, 2010).

Ms. Latimer represents manufacturers, premises owners, contractors, and other corporate members of highly regulated industries in trials and appeals of matters involving such products as prescription and over-the-counter drugs (including contrast dye, anxiety treatments, obstetrical drugs, antifungals, antiseizure medicines, cough/cold medicines, diet aids, osteoporosis drugs, and cancer therapies), prostheses, welding rods, pesticides and herbicides, and manufacturing-use chemical compounds (including detergents, solvents and polychlorinated biphenyls (“PCBs”)).  She is experienced in mass tort, class action, and multi-jurisdiction litigation, and she serves as national trial counsel, regional trial counsel, and Multidistrict Litigation (“MDL”) defense steering committee member in complex toxics matters.  She also counsels clients on due diligence, product registration, and labeling issues, as well as federal and state reporting requirements.

Ms. Latimer has extensive experience in Daubert proceedings and the presentation and cross-examination of expert witnesses in diverse medical and technical fields.  She represents our clients in their most high profile litigation, including cases involving death, encephalopathy, brain, lung, and breast cancer and cancer clusters, stroke, Parkinson’s disease, myocardial infarction, serious skin disorders, immunological injury, bone disease, endocrine disruption, and myriad other serious injuries, as well as cases involving very substantial alleged business losses.  These cases cover the gamut of liability theories, including fraud, conspiracy, and other intentional torts.

Ms. Latimer regularly coordinates amicus curiae support for our clients’ positions and frequently drafts amicus curiae briefs.  She lectures at international and national seminars and private conferences on various aspects of pharmaceutical products liability and toxic tort litigation defense. 

Ms. Latimer is a member of Washington Legal Foundation's Legal Policy Advisory Board, which includes professionals from the government and the legal, academic, and public policy communities.  She is the Consulting Editor and a member of the Advisory Board for the Expert Evidence Reporter published by BNA.  She is a member of the Defense Research Institute (DRI).  Ms. Latimer served on the inaugural Board of Editors for Law360's Product Liability newswire and she was a member of Lexis/Mealey's inaugural Toxic Tort Defense Advisory Council.  She also served as an editorial board member of Mealey’s Litigation Reports: Toxic Torts from 1992 until 1995.  Prior to joining the Firm, she served as judicial clerk to the Hon. Johanna L. Fitzpatrick of the Nineteenth Judicial Circuit of Virginia (subsequently Chief Judge of the Virginia Court of Appeals).

Ms. Latimer is named as a 2018 Litigation Star in Product Liability, U.S. by Benchmark Litigation.  She is listed in the 2018 edition of Super Lawyers for Washington, DC, as she has been each year since 2010.  In 2018, Ms. Latimer is once again named by LMG Life Sciences as a Life Sciences Star, which identifies her as one of the preeminent Life Sciences legal practitioners in the U.S.  She is recognized as a 2018 AV Preeminent® Lawyer by Martindale-Hubbell™, Standard Edition and Judicial Edition.  She is listed in Who's Who in America, Who's Who in American Law, and Who's Who in the East

Ms. Latimer serves on the Grants Committee for Sharing Montgomery, a strategic funding effort operated through The Community Foundation for Montgomery County (Maryland) focusing on nonprofits serving the County's low-income children, families, and seniors.


  • Games People Play: Supreme Court Can Put a Stop to an Obvious CAFA Workaround.
  • Avoiding the Sideshow: One Trial Judge's Textbook Application of Daubert to Exclude Dubious Testimony
  • Washington Legal Foundation publishes "A Framework for Toxic Tort Litigation," by Joe Hollingsworth and Kate Latimer.
  • A Good Bedside Manner Wouldn’t Be Enough Either: Differential Diagnosis Under Daubert

Bloomberg BNA: Monsanto: Cancer Study Suppression is ‘Scientific Vandalism’

Hollingsworth LLP represents Monsanto in In Re:Roundup Products Liability Litigation in the Northern District of California.